{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:44:13Z","timestamp":1786981453277,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11060-024-04850-9","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T04:01:42Z","timestamp":1728878502000},"page":"351-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2\u20133 gliomas"],"prefix":"10.1007","volume":"171","author":[{"given":"Melissa M.","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian F.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Gerstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-9564","authenticated-orcid":false,"given":"Michael W.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"4850_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bpa.12171","volume":"24","author":"DN Louis","year":"2014","unstructured":"Louis DN, Perry A, Burger P (2014) International Society of neuropathology\u2013Haarlem Consensus guidelines for Nervous System Tumor classification and grading. Brain Pathol 24:429\u2013435","journal-title":"Brain Pathol"},{"key":"4850_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97\u2013109","journal-title":"Acta Neuropathol"},{"key":"4850_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2013\u20132017. Neuro-Oncol 22:1\u201396. https:\/\/doi.org\/10.1093\/neuonc\/noaa200","journal-title":"Neuro-Oncol"},{"key":"4850_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2012\u20132016. Neuro-Oncol 21:1\u2013100. https:\/\/doi.org\/10.1093\/neuonc\/noz150","journal-title":"Neuro-Oncol"},{"key":"4850_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a Summary. Neuro-Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-Oncol"},{"key":"4850_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1634\/theoncologist.2009-0291","volume":"15","author":"MJB Taphoorn","year":"2010","unstructured":"Taphoorn MJB, Sizoo EM, Bottomley A (2010) Review on quality of Life issues in patients with primary brain tumors. Oncologist 15:618\u2013626. https:\/\/doi.org\/10.1634\/theoncologist.2009-0291","journal-title":"Oncologist"},{"key":"4850_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/cns.13.65","volume":"3","author":"FW Boele","year":"2014","unstructured":"Boele FW, Klein M, Reijneveld JC, Verdonck-de Leeuw IM, Heimans JJ (2014) Symptom Management and Quality of Life in Glioma patients. CNS Oncol 3:37\u201347. https:\/\/doi.org\/10.2217\/cns.13.65","journal-title":"CNS Oncol"},{"key":"4850_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"4850_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"4850_CR10","doi-asserted-by":"crossref","unstructured":"Prust M (2015) Standard chemoradiation for Glioblastoma Results in Progressive Brain volume loss. Harvard University","DOI":"10.1212\/WNL.0000000000001861"},{"key":"4850_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.radonc.2017.11.033","volume":"128","author":"J Petr","year":"2018","unstructured":"Petr J, Platzek I, Hofheinz F (2018) Photon vs. Proton Radiochemotherapy: effects on Brain tissue volume and perfusion. Radiother Oncol 128:121\u2013127","journal-title":"Radiother Oncol"},{"key":"4850_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijrobp.2011.06.1982","volume":"83","author":"PJ Rauch","year":"2012","unstructured":"Rauch PJ, Park HS, Knisely JPS, Chiang VL, Vortmeyer AO (2012) Delayed Radiation-Induced Vasculitic Leukoencephalopathy. Int J Radiat Oncol 83:369\u2013375","journal-title":"Int J Radiat Oncol"},{"key":"4850_CR13","doi-asserted-by":"publisher","first-page":"10176","DOI":"10.1038\/s41598-021-89216-1","volume":"11","author":"R Terziev","year":"2021","unstructured":"Terziev R, Psimaras D, Marie Y, Feuvret L, Berzero G, Jacob J, Dehais C, Bompaire F, Mueller W, Kinnersley B et al (2021) Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. Sci Rep 11:10176. https:\/\/doi.org\/10.1038\/s41598-021-89216-1","journal-title":"Sci Rep"},{"key":"4850_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1212\/WNL.0000000000012150","volume":"97","author":"SF Winter","year":"2021","unstructured":"Winter SF, Klein JP, Vaios EJ (2021) Clinical presentation and management of SMART Syndrome. Neurology 97:118\u2013120","journal-title":"Neurology"},{"key":"4850_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11060-015-1839-5","volume":"124","author":"AA Aizer","year":"2015","unstructured":"Aizer AA, Du R, Wen PY, Arvold ND (2015) Radiotherapy and Death from Cerebrovascular Disease in patients with primary brain tumors. J Neurooncol 124:291\u2013297","journal-title":"J Neurooncol"},{"key":"4850_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.0000000000003631","volume":"88","author":"D Roongpiboonsopit","year":"2017","unstructured":"Roongpiboonsopit D, Kuijf HJ, Charidimou A (2017) Evolution of cerebral microbleeds after Cranial Irradiation in Medulloblastoma patients. Neurology 88:789\u2013796","journal-title":"Neurology"},{"key":"4850_CR17","doi-asserted-by":"crossref","unstructured":"Winter SF, Loebel F, Loeffler J (2019) Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro Oncol 21","DOI":"10.1093\/neuonc\/noz048"},{"key":"4850_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/neuonc\/nos307","volume":"15","author":"N Verma","year":"2013","unstructured":"Verma N, Cowperthwaite MC, Burnett MG, Markey MK (2013) Differentiating Tumor recurrence from treatment necrosis: a review of Neuro-oncologic imaging strategies. Neuro Oncol 15:515\u2013534","journal-title":"Neuro Oncol"},{"key":"4850_CR19","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1634\/theoncologist.2020-0085","volume":"25","author":"SF Winter","year":"2020","unstructured":"Winter SF, Vaios EJ, Muzikansky A, Martinez-Lage M, Bussi\u00e8re MR, Shih HA, Loeffler J, Karschnia P, Loebel F, Vajkoczy P et al (2020) Defining treatment-related adverse effects in patients with glioma: distinctive features of Pseudoprogression and Treatment-Induced necrosis. Oncologist 25:e1221\u2013e1232. https:\/\/doi.org\/10.1634\/theoncologist.2020-0085","journal-title":"Oncologist"},{"key":"4850_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1212\/WNL.0000000000001861","volume":"85","author":"MJ Prust","year":"2015","unstructured":"Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J (2015) Standard chemoradiation for Glioblastoma Results in Progressive Brain volume loss. Neurology 85:683\u2013691. https:\/\/doi.org\/10.1212\/WNL.0000000000001861","journal-title":"Neurology"},{"key":"4850_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/nox217","volume":"20","author":"ML Prust","year":"2018","unstructured":"Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J (2018) Standard chemoradiation in combination with VEGF targeted therapy for Glioblastoma Results in Progressive Gray and White Matter volume loss. Neuro Oncol 20:289\u2013291","journal-title":"Neuro Oncol"},{"key":"4850_CR22","doi-asserted-by":"publisher","first-page":"vii201","DOI":"10.1093\/neuonc\/noac209.773","volume":"24","author":"O Akintola","year":"2022","unstructured":"Akintola O, Dietrich J, Muzikansky A, Melissa G, Youssef G, Huang R, Gerstner E, Wen PY, Parsons M, Gilbert M et al (2022) NCOG-20. Brain atrophy in glioblastoma patients following treatment with chemoradiation or chemoradiation with anti-angiogenic therapy in NRG\/RTOG 0825 participants. Neuro-Oncol 24:vii201. https:\/\/doi.org\/10.1093\/neuonc\/noac209.773","journal-title":"Neuro-Oncol"},{"key":"4850_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1634\/theoncologist.2008-0130","volume":"13","author":"J Dietrich","year":"2008","unstructured":"Dietrich J, Monje M, Wefel J, Meyers C (2008) Clinical patterns and Biological correlates of Cognitive Dysfunction Associated with Cancer Therapy. Oncologist 13:1285\u20131295. https:\/\/doi.org\/10.1634\/theoncologist.2008-0130","journal-title":"Oncologist"},{"key":"4850_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","volume":"13","author":"JB Stone","year":"2016","unstructured":"Stone JB, DeAngelis LM (2016) Cancer-Treatment-Induced neurotoxicity\u2013focus on newer treatments. Nat Rev Clin Oncol 13:92\u2013105. https:\/\/doi.org\/10.1038\/nrclinonc.2015.152","journal-title":"Nat Rev Clin Oncol"},{"key":"4850_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1474-4422(04)00680-5","volume":"3","author":"MJ Taphoorn","year":"2004","unstructured":"Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3:159\u2013168. https:\/\/doi.org\/10.1016\/S1474-4422(04)00680-5","journal-title":"Lancet Neurol"},{"key":"4850_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/neuonc\/nox195","volume":"20","author":"C Wilke","year":"2018","unstructured":"Wilke C, Grosshans D, Duman J, Brown P, Li J (2018) Radiation-Induced Cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults. Neuro Oncol 20:597\u2013607","journal-title":"Neuro Oncol"},{"key":"4850_CR27","doi-asserted-by":"publisher","unstructured":"Kaiser J, Bledowski C, Dietrich J (2014) Neural correlates of Chemotherapy-related cognitive impairment. Cortex 54. https:\/\/doi.org\/10.1016\/j.cortex.2014.01.010","DOI":"10.1016\/j.cortex.2014.01.010"},{"issue":"9","key":"4850_CR28","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1200\/JCO.1995.13.9.2263","volume":"13","author":"C Armstrong","year":"1995","unstructured":"Armstrong C, Ruffer J, Corn B, DeVries K, Mollman J (1995) Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: neuropsychologic outcome and proposed mechanisms. J Clin Oncol 13(9):2263\u20132271. https:\/\/doi.org\/10.1200\/JCO.1995.13.9.2263","journal-title":"J Clin Oncol"},{"key":"4850_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-006-0026-5","author":"JM Butler","year":"2006","unstructured":"Butler JM, Rapp S (2006) Managing the Cognitive effects of Brain Tumor Radiation Therapy. Curr Treat Options Oncol. https:\/\/doi.org\/10.1007\/s11864-006-0026-5","journal-title":"Curr Treat Options Oncol"},{"key":"4850_CR30","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/wnl.56.10.1285","volume":"56","author":"O Surma-aho","year":"2001","unstructured":"Surma-aho O, Niemel\u00e4 M, Vilkki J, Kouri M, Brander A, Salonen O, Paetau A, Kallio M, Pyykk\u00f6nen J, J\u00e4\u00e4skel\u00e4inen J (2001) Adverse Long-Term effects of Brain Radiotherapy in Adult Low-Grade Glioma patients. Neurology 56:1285\u20131290. https:\/\/doi.org\/10.1212\/wnl.56.10.1285","journal-title":"Neurology"},{"key":"4850_CR31","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/s0140-6736(02)11398-5","volume":"360","author":"M Klein","year":"2002","unstructured":"Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN et al (2002) Effect of Radiotherapy and Other Treatment-related factors on Mid-term to Long-Term Cognitive Sequelae in Low-Grade gliomas: a comparative study. Lancet Lond Engl 360:1361\u20131368. https:\/\/doi.org\/10.1016\/s0140-6736(02)11398-5","journal-title":"Lancet Lond Engl"},{"key":"4850_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","volume":"8","author":"L Douw","year":"2009","unstructured":"Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH et al (2009) Cognitive and Radiological effects of Radiotherapy in patients with low-Grade Glioma: Long-Term Follow-Up. Lancet Neurol 8:810\u2013818. https:\/\/doi.org\/10.1016\/S1474-4422(09)70204-2","journal-title":"Lancet Neurol"},{"key":"4850_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/neuonc\/noaa252","volume":"23","author":"M Klein","year":"2021","unstructured":"Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP et al (2021) Memory in low-Grade Glioma patients treated with Radiotherapy or Temozolomide: a correlative analysis of EORTC Study 22033\u201326033. Neuro-Oncol 23:803\u2013811. https:\/\/doi.org\/10.1093\/neuonc\/noaa252","journal-title":"Neuro-Oncol"},{"key":"4850_CR34","doi-asserted-by":"publisher","first-page":"105239","DOI":"10.1016\/j.yrtph.2022.105239","volume":"134","author":"CR Kirman","year":"2022","unstructured":"Kirman CR, North CM, Tretyakova NY, Erraguntla N, Shen H, Hays SM (2022) Use of Biomarker Data and Metabolite relative potencies to support derivation of Noncancer reference values based on the Reproductive and Developmental Toxicity effects of 1,3-Butadiene. Regul Toxicol Pharmacol 134:105239. https:\/\/doi.org\/10.1016\/j.yrtph.2022.105239","journal-title":"Regul Toxicol Pharmacol"},{"key":"4850_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","volume":"366","author":"MJ van den Bent","year":"2005","unstructured":"van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstr\u00f6m P-O, Collette L, Pi\u00e9rart M, Mirimanoff R et al (2005) Long-term efficacy of early versus delayed Radiotherapy for Low-Grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 Randomised Trial. Lancet Lond Engl 366:985\u2013990. https:\/\/doi.org\/10.1016\/S0140-6736(05)67070-5","journal-title":"Lancet Lond Engl"},{"key":"4850_CR36","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/s0959-8049(98)00268-8","volume":"34","author":"GM Kiebert","year":"1998","unstructured":"Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, Nordman E, Silvestre ME, Pierart M, Karim AB (1998) Quality of life after Radiation Therapy of Cerebral Low-Grade gliomas of the Adult: results of a Randomised Phase III Trial on Dose Response (EORTC Trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer Oxf Engl 1990 34:1902\u20131909. https:\/\/doi.org\/10.1016\/s0959-8049(98)00268-8","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"4850_CR37","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","volume":"17","author":"BG Baumert","year":"2016","unstructured":"Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB et al (2016) Temozolomide Chemotherapy versus Radiotherapy in High-Risk Low-Grade Glioma. Lancet Oncol 17:1521\u20131532. https:\/\/doi.org\/10.1016\/S1470-2045(16)30313-8","journal-title":"Lancet Oncol"},{"key":"4850_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s0360-3016(96)00352-5","volume":"36","author":"AB Karim","year":"1996","unstructured":"Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M et al (1996) A randomized trial on dose-response in Radiation Therapy of Low-Grade Cerebral Glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549\u2013556. https:\/\/doi.org\/10.1016\/s0360-3016(96)00352-5","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4850_CR39","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2002.09.126","volume":"20","author":"E Shaw","year":"2002","unstructured":"Shaw E, Arusell R, Scheithauer B, O\u2019Fallon J, O\u2019Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T et al (2002) Prospective randomized trial of low- versus high-dose Radiation Therapy in adults with Supratentorial Low-Grade Glioma: initial report of a North Central Cancer Treatment Group\/Radiation Therapy Oncology Group\/Eastern Cooperative Oncology Group Study. J Clin Oncol off J Am Soc Clin Oncol 20:2267\u20132276. https:\/\/doi.org\/10.1200\/JCO.2002.09.126","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"4850_CR40","doi-asserted-by":"crossref","unstructured":"DeAngelis LM, Mandell LR, Thaler TH, Kimmel DW, Galicich JH, Fuks Z, Posner JB (1989) The Role of Postoperative Radiotherapy after Resection of Single Brain Metastases. Neurosurgery 24","DOI":"10.1097\/00006123-198906000-00002"},{"key":"4850_CR41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.39.6.789","volume":"39","author":"M Lisa","year":"1989","unstructured":"Lisa M (1989) DeAngelis; Jean-Yves Delattre; Jerome B. Posner Radiation-induced dementia in patients cured of Brain metastases. Neurology 39:789. https:\/\/doi.org\/10.1212\/WNL.39.6.789","journal-title":"Neurology"},{"key":"4850_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1088\/0031-9155\/60\/8\/R155","volume":"60","author":"WD Newhauser","year":"2015","unstructured":"Newhauser WD, Zhang R (2015) The physics of Proton Therapy. Phys Med Biol 60:155\u2013209. https:\/\/doi.org\/10.1088\/0031-9155\/60\/8\/R155","journal-title":"Phys Med Biol"},{"key":"4850_CR43","doi-asserted-by":"publisher","unstructured":"Jhaveri J, Cheng E, Tian S (2018) Proton vs. Photon Radiation Therapy for primary gliomas: an analysis of the National Cancer Data Base. Front Oncol 8. https:\/\/doi.org\/10.3389\/fonc.2018.00440","DOI":"10.3389\/fonc.2018.00440"},{"key":"4850_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","volume":"109","author":"R Mohan","year":"2017","unstructured":"Mohan R, Grosshans D (2017) Proton therapy - Present and future. Adv Drug Deliv Rev 109:26\u201344","journal-title":"Adv Drug Deliv Rev"},{"key":"4850_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","volume":"109","author":"R Mohan","year":"2017","unstructured":"Mohan R, Grosshans D (2017) Proton Therapy \u2013 Present and Future. Adv Drug Deliv Rev 109:26\u201344. https:\/\/doi.org\/10.1016\/j.addr.2016.11.006","journal-title":"Adv Drug Deliv Rev"},{"key":"4850_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.phro.2021.11.008","volume":"20","author":"CS Byskov","year":"2021","unstructured":"Byskov CS, Hansen CR, Dahlrot RH, Haldbo-Classen L, Haslund CA, Kj\u00e6r-Kristoffersen F, Kristensen TO, Lassen-Ramshad Y, Lukacova S, Muhic A et al (2021) Treatment plan comparison of Proton vs Photon Radiotherapy for Lower-Grade Gliomas. Phys Imaging Radiat Oncol 20:98\u2013104. https:\/\/doi.org\/10.1016\/j.phro.2021.11.008","journal-title":"Phys Imaging Radiat Oncol"},{"key":"4850_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.radonc.2021.12.035","volume":"167","author":"SB Harrabi","year":"2021","unstructured":"Harrabi SB, Nettelbladt B, Gudden C (2021) Radiation Induced Contrast Enhancement after Proton Beam Therapy in patients with low Grade glioma \u2013 how safe are protons? Radiother Oncol 167:211\u2013218","journal-title":"Radiother Oncol"},{"key":"4850_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/sj.bjc.6602754","volume":"93","author":"WP Levin","year":"2005","unstructured":"Levin WP, Kooy H, Loeffler JS, DeLaney TF (2005) Proton Beam Therapy. Br J Cancer 93:849\u2013854. https:\/\/doi.org\/10.1038\/sj.bjc.6602754","journal-title":"Br J Cancer"},{"key":"4850_CR49","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","volume":"23","author":"PD Brown","year":"2021","unstructured":"Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer M-F et al (2021) A prospective phase II randomized trial of Proton Radiotherapy vs intensity-modulated Radiotherapy for patients with newly diagnosed Glioblastoma. Neuro-Oncol 23:1337\u20131347. https:\/\/doi.org\/10.1093\/neuonc\/noab040","journal-title":"Neuro-Oncol"},{"key":"4850_CR50","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/cncr.29237","volume":"121","author":"HA Shih","year":"2015","unstructured":"Shih HA, Sherman JC, Nachtigall LB (2015) Proton Therapy for Low-Grade gliomas: results from a prospective trial. Cancer 121:1712\u20131719","journal-title":"Cancer"},{"key":"4850_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-015-1952-5","volume":"126","author":"J Sherman","year":"2016","unstructured":"Sherman J, Colvin M, Mancuso S, Batchelor T, Oh K, Loeffler J, Shih H (2016) Neurocognitive effects of Proton Radiation Therapy in adults with Low-Grade Glioma. J Neurooncol 126:157\u2013164. https:\/\/doi.org\/10.1007\/s11060-015-1952-5","journal-title":"J Neurooncol"},{"key":"4850_CR52","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association World Medical Association Declaration of Helsinki (2013) Ethical principles for Medical Research Involving human subjects. JAMA 310:2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"4850_CR53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/nox217","volume":"20","author":"ML Prust","year":"2018","unstructured":"Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J (2018) Standard chemoradiation in combination with VEGF targeted therapy for Glioblastoma Results in Progressive Gray and White Matter volume loss. Neuro-Oncol 20:289\u2013291. https:\/\/doi.org\/10.1093\/neuonc\/nox217","journal-title":"Neuro-Oncol"},{"key":"4850_CR54","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.2005.04.6086","volume":"24","author":"CA Meyers","year":"2006","unstructured":"Meyers CA, Brown PD (2006) Role and relevance of Neurocognitive Assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305\u20131309. https:\/\/doi.org\/10.1200\/JCO.2005.04.6086","journal-title":"J Clin Oncol"},{"key":"4850_CR55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","volume":"12","author":"JS Wefel","year":"2011","unstructured":"Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with Cancer. Lancet Oncol 12:703\u2013708. https:\/\/doi.org\/10.1016\/S1470-2045(10)70294-1","journal-title":"Lancet Oncol"},{"key":"4850_CR56","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/13803395.2019.1571169","volume":"41","author":"J Durant","year":"2019","unstructured":"Durant J, Duff K, Miller JB (2019) Regression-based formulas for Predicting Change in Memory Test scores in healthy older adults: comparing Use of Raw versus standardized scores. J Clin Exp Neuropsychol 41:460\u2013468. https:\/\/doi.org\/10.1080\/13803395.2019.1571169","journal-title":"J Clin Exp Neuropsychol"},{"key":"4850_CR57","doi-asserted-by":"publisher","unstructured":"Duff K (2012) Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol 27(3):248-261. https:\/\/doi.org\/10.1093\/arclin\/acs034","DOI":"10.1093\/arclin\/acs034"},{"key":"4850_CR58","doi-asserted-by":"publisher","unstructured":"Winter SF, Gardner MM, Karschnia P, Vaios EJ, Grassberger C, Brussiere MR, Nikolic K, Pongpitakmetha T, Ehret F, Kaul D, Boehmerle W, Endres M, Shih H, Parsons MW, Dietrich J (2024) Unique brain injury patterns after proton vs photon radiotherapy for WHO grade 2\u20133 gliomas. Oncologist oyae195. https:\/\/doi.org\/10.1093\/oncolo\/oyae195","DOI":"10.1093\/oncolo\/oyae195"},{"key":"4850_CR59","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492\u2013507. https:\/\/doi.org\/10.1056\/NEJMra0708126","journal-title":"N Engl J Med"},{"key":"4850_CR60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/noac207","volume":"25","author":"JJ Miller","year":"2023","unstructured":"Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS et al (2023) Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) Consensus Review on diagnosis, management, and future directions. Neuro-Oncol 25:4\u201325. https:\/\/doi.org\/10.1093\/neuonc\/noac207","journal-title":"Neuro-Oncol"},{"key":"4850_CR61","doi-asserted-by":"crossref","unstructured":"Eekers DB, Zegers CM, Ahmed KA, Amelio D, Gupta T, Harrabi SB, Kazda T, Scartoni D, Seidel C, Shih HA, Minniti G (2024) Controversies in neuro-oncology: focal proton versus photon radiation therapy for adult brain tumors. Neuro-Oncology Practice, p npae040","DOI":"10.1093\/nop\/npae040"},{"key":"4850_CR62","doi-asserted-by":"publisher","first-page":"856808","DOI":"10.3389\/fnins.2022.856808","volume":"16","author":"Z Chen","year":"2022","unstructured":"Chen Z, Ye N, Teng C, Li X (2022) Alternations and applications of the Structural and Functional Connectome in Gliomas: a Mini-review. Front Neurosci 16:856808. https:\/\/doi.org\/10.3389\/fnins.2022.856808","journal-title":"Front Neurosci"},{"key":"4850_CR63","unstructured":"Oncology NRG (2022) National Cancer Institute (NCI. In NCT03180502: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04850-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T19:07:24Z","timestamp":1735844844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04850-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4850"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04850-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4973431\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. All research procedures were conducted with the approval of the Institutional Review Board of Mass General Brigham.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Michael W. Parsons serves as a consultant to Servier Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}